Hantz Financial Services Inc. Lowers Position in Grifols, S.A. (NASDAQ:GRFS)

Hantz Financial Services Inc. trimmed its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 234,565 shares of the biotechnology company’s stock after selling 7,247 shares during the quarter. Hantz Financial Services Inc.’s holdings in Grifols were worth $1,745,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in GRFS. GAMMA Investing LLC raised its position in shares of Grifols by 49.4% in the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 1,135 shares during the period. NBC Securities Inc. raised its holdings in Grifols by 2.8% in the 3rd quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 1,433 shares during the period. HighTower Advisors LLC boosted its position in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 1,546 shares in the last quarter. Signaturefd LLC grew its holdings in Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the period. Finally, US Bancorp DE raised its stake in shares of Grifols by 12.3% during the 3rd quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock worth $183,000 after buying an additional 2,256 shares during the period.

Analyst Ratings Changes

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Stock Performance

GRFS stock opened at $6.91 on Friday. Grifols, S.A. has a 52 week low of $5.30 and a 52 week high of $9.96. The firm has a 50-day simple moving average of $7.53 and a 200-day simple moving average of $8.15. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.